A Randomized, Double-Blind, Comparison of Denosumab versus Zoledronic Acid on Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer

Meiru Yan

doi:10.54254/2753-8818/2025.20472

Article Information

Received: 26 November 2024

Published: 15 January 2025

DOI: https://doi.org/10.54254/2753-8818/2025.20472

Article Type: Research Article

Cite this article

Yan,M. (2025). A Randomized, Double-Blind, Comparison of Denosumab versus Zoledronic Acid on Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer. Theoretical and Natural Science,68,245-250.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About this Volume

Volume Title: TNS Vol.68

Part of Series: Theoretical and Natural Science

ISSN: 2753-8818 (Print) / 2753-8826 (Online)

Copyright & License

[1]Schatten H. Brief overview of prostate cancer statistics, grading, diagnosis, and treatment strategies. Adv Exp Med Biol. 2018;1095:1-14.

[2]Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal-related events, bone metastasis, and survival of prostate cancer: A population-based cohort study in Denmark (1999 to 2007). J Urol. 2010.

[3]Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer. 2007.

[4]National Cancer Institute. Denosumab prevents bone fractures in prostate cancer. Available from: https://www.cancer.gov/types/prostate/research/denosumab-bone-fractures.

[5]Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Goessl C. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomized, placebo-controlled trial. Lancet. 2012;379(9810):39-46.

[6]Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer. Lancet. 2011;377(9768):813-822.

[7]Smith MR, Saad F, Coleman R, Shore ND, Fizazi K, Tombal B, Goessl C. Long-term efficacy and safety of denosumab in men with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2015;33(35):4037-4045.

[8]Smith MR, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23.

[9]Henry DH, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases. J Clin Oncol. 2011;29(9):1125-1132.